Bone problems

Bone problems features

• 

  Skeleton key: a guide to HIV-related bone loss

  Many people with HIV are at risk of osteoporosis – a progressive thinning of the bones that can lead to breakage. Derek Thaczuk looks at who...

  From:  HIV treatment update

Bone problems news from aidsmap

• New pro-drug tenofovir alafenamide appears equally effective but better tolerated

  Tenofovir alafenamide fumarate or TAF (formerly GS-7340), a new pro-drug of the widely used NRTI tenofovir, reaches cells harbouring HIV more easily than the older tenofovir disoproxil fumarate (TDF), allowing for similar antiviral efficacy with smaller doses and with ...

  07 March 2013 | Liz Highleyman

• Frailty increases the risk of fragility fractures in men living with HIV: data collected in routine HIV care can help predict risk

  Important physiologic markers of frailty are associated with fragility fractures in men living with HIV, according to research conducted in the United States and published in the online edition of Clinical Infectious Diseases. “Among HIV-infected men, physiologic frailty…is strongly ...

  18 February 2013 | Michael Carter

• Co-infection with hepatitis B or C is a risk factor for reduced bone mineral density among women with HIV

  Co-infection with hepatitis B or C is associated with reduced bone mineral density (BMD) in women living with HIV, French investigators report in the online edition of the Journal of Acquired Immune Deficiency Syndromes. The investigators compared bone mineral ...

  28 January 2013 | Michael Carter

• Dutch find low bone mineral density in gay men, regardless of HIV infection status

  The prevalence of low bone mineral density (BMD) is similar in HIV-positive and HIV-negative gay men, according to the results of Dutch research published in the online edition of the Journal of Infectious Diseases. The only significant risk factor ...

  26 November 2012 | Michael Carter

• Low bone density present in young men taking HIV therapy

  HIV infection in young men is associated with reduced bone mineral density, US investigators report in the online edition of Clinical Infectious Diseases. Antiretroviral therapy based on a protease inhibitor was especially associated with reduced bone density. “We report evidence ...

  04 July 2012 | Michael Carter

• HIV/hepatitis C co-infection increases risk of hip fracture

  Co-infection with HIV and hepatitis C is associated with an increased risk of hip fracture, US investigators report in Hepatology. Hepatitis C monoinfection also increased the risk of this type of fracture. The authors suggest that this elevation in ...

  19 June 2012 | Michael Carter

• HIV treatment reduces risk of fractures

  Treatment with antiretroviral drugs reduces the risk of low-impact fractures, according to a case-controlled study published in the on-line edition of AIDS. Investigators compared fracture incidence between patients taking HIV therapy and non-treated individuals. Despite the overall beneficial effect of treatment, ...

  14 February 2012 | Michael Carter

• Vitamin D supplements benefit bone metabolism of younger patients taking tenofovir

  Vitamin D supplementation is associated with an improvement in a key marker of bone health in HIV-positive young adults treated with tenofovir, US research published in Clinical Infectious Diseases shows. Treatment with vitamin D3 led to a significant fall in parathyroid ...

  25 January 2012 | Michael Carter

• Limited evidence that vitamin D supplements of any benefit for patients with HIV

  There is only scant evidence that vitamin D supplementation is of benefit for patients with HIV, according to UK investigators writing in the January 28th  edition of AIDS. The authors conducted a systematic review of studies examining the prevalence ...

  10 January 2012 | Michael Carter

• Raltegravir kinder to bones and body fat than boosted protease inhibitors in Spanish trial

  Raltegravir (Isentress)-based treatment appears to have a more favourable impact on fat accumulation and bone metabolism compared to therapy based on a ritonavir-boosted protease inhibitor, according to Spanish research published in the online edition of AIDS. The study involved ...

  28 November 2011 | Michael Carter

More news

Bone problems news selected from other sources

• Bone mineral density below normal in children infected early with HIV

  Bone mineral density was below the general population norm in US children perinatally infected with HIV and lower than in children perinatally exposed to HIV but uninfected.

  21 January 2013 | International AIDS Society

• HIV treatment interruption associated with reduced bone loss in SMART trial

  People who stopped antiretroviral therapy in the SMART trial had less bone loss and lower levels of bone metabolism biomarkers than people who remained on continuous antiretroviral therapy (ART), according to a report in the January 8, 2013, advance edition of Journal of Bone Mineral Research.

  16 January 2013 | HIVandHepatitis.com

• Activist discusses challenge of growing old with HIV

  Old age comes faster and hits harder for those infected with HIV, a fact aging health activist Ron Swanda knows all too well.

  30 November 2012 | AFP

• Weekly alendronate improves bone density in adults taking ART

  Alendronate significantly improved bone mineral density through 96 weeks of treatment in a double-blind placebo-controlled trial that enrolled adults with osteoporosis while taking antiretroviral therapy (ART).

  30 August 2012 | International AIDS Society

• High Dose Vitamin D Prevents Fractures

  High doses of vitamin D prevent fractures in older people – as long as they take the substance regularly.

  05 July 2012 | Medical News Today

• Treatment Update: Bone Health

  Many studies have found that some HIV-positive people tend to have bones that are not as thick or dense as they ought to be. Such bones have reduced bone mineral density, as minerals such as calcium have been removed, rendering the bones more porous and weak.

  28 May 2012 | CATIE

• Bisphosphonate Drugs Linked to Atypical Femur Fractures, but Absolute Risk is Small

  Use of bisphosphonates, a class of drugs used to manage bone loss and prevent fractures, actually appears to increase the likelihood of an unusual type of femur (thigh bone) fracture, according to a retrospective analysis described in the advance online edition of Archives of Internal Medicine. Researchers emphasized, however, that the absolute risk of atypical femur breaks remains very low.

  28 May 2012 | HIVandHepatitis.com

• Zoledronate Protects HIV Positive Men against Bone Loss for at Least 5 Years

  The effects of 2 annual doses of zoledronate persist for at least 5 years in HIV positive men on antiretroviral therapy (ART), according to a New Zealand study published in the March 14, 2012, advance online edition of the Journal of Clinical Endocrinology & Metabolism.

  11 April 2012 | HIVandHepatitis.com

• CROI: Switching to Tenofovir Increases Bone Turnover, Raltegravir Can Improve Bone Density

  HIV positive people who substituted tenofovir (Viread) for zidovudine (AZT; Retrovir) in their antiretroviral regimen showed elevated levels of biomarkers associated with bone turnover and decreased bone mineral density (BMD), researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last month in Seattle.

  11 April 2012 | HIVandHepatitis.com

• Vitamin D May Improve Bone Health in Those Taking Anti-HIV Drug

  A new NIH-funded study indicates that taking Vitamin D supplements can help prevent hormonal changes that lead to bone loss amongst patients taking tenofovir (Viread) for the long-term treatment of HIV.

  12 January 2012 | National Institutes of Health press release

More news